<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">medRxiv</journal-id><journal-id journal-id-type="publisher-id">MEDRXIV</journal-id><journal-title-group><journal-title>medRxiv</journal-title></journal-title-group><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40385401</article-id><article-id pub-id-type="pmc">PMC12083634</article-id>
<article-id pub-id-type="doi">10.1101/2025.05.09.25327351</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Testing for Causal Association between Serum Urate, Gout, and Prostatic Cancer in European Males</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9522-4020</contrib-id><name><surname>Chandrupatla</surname><given-names>Sumanth R.</given-names></name><degrees>B.S.</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="FN1" ref-type="author-notes">^</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0451-9024</contrib-id><name><surname>Sumpter</surname><given-names>Nicholas</given-names></name><degrees>Ph.D.</degrees><xref rid="A3" ref-type="aff">3</xref><xref rid="FN1" ref-type="author-notes">^</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1243-2535</contrib-id><name><surname>Takei</surname><given-names>Riku</given-names></name><degrees>MSC</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0844-8726</contrib-id><name><surname>Merriman</surname><given-names>Tony R.</given-names></name><degrees>Ph.D.</degrees><xref rid="A2" ref-type="aff">2</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3485-0006</contrib-id><name><surname>Singh</surname><given-names>Jasvinder A.</given-names></name><degrees>MBBS, MPH</degrees><xref rid="A4" ref-type="aff">4</xref><xref rid="A5" ref-type="aff">5</xref></contrib></contrib-group><aff id="A1"><label>1</label>Heersink School of Medicine, University of Alabama at Birmingham, AL, United States</aff><aff id="A2"><label>2</label>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL, United States</aff><aff id="A3"><label>3</label>Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands</aff><aff id="A4"><label>4</label>Medicine Service, Michael E. DeBakey VA Medical Center, 2002 Holcombe Blvd, Houston, TX 77030, USA</aff><aff id="A5"><label>5</label>Department of Medicine, Baylor College of Medicine, 7200 Cambridge Street, Houston, TX 77030, USA.</aff><author-notes><fn fn-type="equal" id="FN1"><label>^</label><p id="P1">These authors contributed equally</p></fn><corresp id="CR1"><label>*</label><bold>Correspondence:</bold> Tony R. Merriman, University of Alabama at Birmingham, Shelby Building, Room 202, 1825 University Boulevard, Birmingham, AL 35233, USA, <email>trmerriman@uabmc.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>5</month><year>2025</year></pub-date><elocation-id>2025.05.09.25327351</elocation-id><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</ext-link>, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.</license-p></license></permissions><self-uri content-type="pdf">nihpp-2025.05.09.25327351.pdf</self-uri><abstract id="ABS1"><sec id="S1"><title>Objective:</title><p id="P2">To conduct a two-sample MR study including only men to test for a causal relationship between serum urate (SU) and gout and prostate cancer.</p></sec><sec id="S2"><title>Methods:</title><p id="P3">We used GWAS for SU, gout, and prostate cancer to generate exposure instrumental variables (IV) associated with gout and urate. We used 20 single nucleotide polymorphisms (SNPs) associated with gout but not urate for an IV representing the non-hyperuricemia (inflammatory) compartment of gout and we used four SNPs from loci containing urate transporter genes for an IV representing urate levels. MR methods included inverse-variance-weighted (IVW), MR-Egger regression, and weighted median to test for causal relationships and horizontal pleiotropy.</p></sec><sec id="S3"><title>Results:</title><p id="P4">The non-hyperuricemia compartment of gout IV showed a causal effect of gout on prostate cancer (Weighted median: <italic toggle="yes">P</italic> = 0.01). In contrast, the SU IV showed no evidence for a causal effect of SU on prostate cancer (IVW: <italic toggle="yes">P</italic> = 0.83; Weighted Median: <italic toggle="yes">P</italic> = 0.97). We found no evidence of horizontal pleiotropy from MR-Egger for either the urate or gout IV (non-hyperuricemia compartment of gout: <italic toggle="yes">P</italic> = 0.33; urate: <italic toggle="yes">P</italic> = 0.80). Loci contributing most strongly to the non-hyperuricemia causal effect included three genes: <italic toggle="yes">IL1R1, IL1RN</italic>, and <italic toggle="yes">SLC30A5</italic>. There was no evidence for a causal relationship of prostate cancer on gout or SU.</p></sec><sec id="S4"><title>Conclusion:</title><p id="P5">MR analysis in a European male population found evidence for a causal effect between the non-hyperuricemia compartment of gout and prostate cancer. Implication of the <italic toggle="yes">IL1R1</italic> and <italic toggle="yes">IL1RN</italic> genes directly implicates the gouty inflammation pathway in prostate cancer.</p></sec></abstract></article-meta></front><body><sec id="S5"><title>Introduction</title><p id="P6">Gout is an inflammatory disorder characterized by elevation of SU that manifests as local and systemic inflammation secondary to monosodium urate (MSU) crystal deposition in joints and other tissues. If left untreated, gout frequently manifests as recurrent episodes of acute inflammation that are very painful and severely disabling, potentially increasing the risk of comorbidities including heart failure, myocardial infarction, chronic kidney disease stage &#x02265;2 and diabetes (<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R3" ref-type="bibr">3</xref>). Gout affects approximately 5.1% of adults in the US, with ~3-fold increased prevalence in men, and men have elevated SU levels compared to women (<xref rid="R4" ref-type="bibr">4</xref>&#x02013;<xref rid="R7" ref-type="bibr">7</xref>). There is evidence that the prostate plays a role in urate homeostasis in men, with urate being present in human semen, and urate crystals being found in 47.5% of non-malignant prostate sections (<xref rid="R8" ref-type="bibr">8</xref>&#x02013;<xref rid="R10" ref-type="bibr">10</xref>). Additionally, gout is associated with an increased risk of benign prostatic hyperplasia (BPH) and treatment with the urate-lowering drug allopurinol decreases the risk of BPH, indicating that the presence of higher urate levels and gout may both contribute to prostatic enlargement (<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R12" ref-type="bibr">12</xref>). BPH shares a number of features with prostate cancer, including hormone-dependent growth and metabolic disruption playing key roles in disease development, and a causal relationship between BPH and prostate cancer has recently been established (<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R14" ref-type="bibr">14</xref>).</p><p id="P7">Mendelian randomization (MR) is a genetic epidemiological approach to establish causality between two phenotypes by testing genetic variants (instrumental variable) associated with increased risk of the exposure with the outcome (<xref rid="R17" ref-type="bibr">17</xref>). One advantage of using MR is that genetic variants are fixed at conception, making the method robust to the influence of confounding factors (<xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R16" ref-type="bibr">16</xref>). Previous studies using MR examined whether a causal relationship exists between urate and prostate cancer (<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>), though none have tested the association of gout with prostate cancer. Studies that have examined genetic links between SU and prostate cancer have had contradictory findings. In an East Asian cohort, increased urate levels were causally associated with prostate cancer, but no causal relationship was found in a European cohort (<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>). However, these studies included females in the GWAS for development of the SU instrumental variable. Since females have lower SU levels (<xref rid="R5" ref-type="bibr">5</xref>), and prostate cancer only affects males, the results found from these studies may be biased.</p><p id="P8">Due to the genetic and epidemiological evidence of a potential relationship between gout, urate, prostatic inflammation, and prostate cancer, limitations with previous MR studies, and the fact that gout has not yet been examined as an exposure in prostate cancer MR, we aimed to identify whether there was a potential causal relationship between urate, gout-related inflammation, and prostate cancer. Unlike all previous MR studies in gout, we isolated the non-hyperuricemic (inflammatory) compartment of gout and tested this signal along with urate transport genes against prostate-cancer risk.</p></sec><sec id="S6"><title>Methods</title><sec id="S7"><title>Exposure instrumental variable and outcome GWAS summary statistics for two-sample MR study</title><p id="P9">Our study was designed to identify any potential causal effects of SU and of the non-hyperuricemia compartment of gout on prostate cancer risk. Since prostate cancer is a male-only condition, we identified male-only genome-wide association studies (GWAS) of SU and gout, and used effect sizes from these studies in the MR analysis. We used previously published European ancestry male-only gout and SU GWAS (<xref rid="R19" ref-type="bibr">19</xref>). The gout GWAS contained 77,628 cases and 933,894 controls, and the SU GWAS contained a total of 145,625 men aged 40&#x02013;69 with complete SU measurements from the UK Biobank (project number 12611). The prostate cancer GWAS was sourced from Wang, et al. and contained 122,188 cases and 604,640 male controls of European ancestry (<xref rid="R20" ref-type="bibr">20</xref>).</p></sec><sec id="S8"><title>Statistical Analysis</title><p id="P10">We selected gout instrumental variables (IVs) from the gout GWAS to represent the non-hyperuricemia compartment of gout. This was determined previously by Major, et al. by conducting colocalization analysis between the lead variants for signals in gout and SU (<xref rid="R19" ref-type="bibr">19</xref>), where lead SNPs from signals with posterior probabilities for H1 or H3 &#x02265; 0.8 represented an association with gout but not urate, and therefore the non-hyperuricemia compartment of gout (such as promotion of gout inflammation and deposition of MSU crystals). The lead SNPs from these genetic signals were used for MR analysis as IVs (<xref rid="R19" ref-type="bibr">19</xref>). SU IVs were selected as the lead SNPs from the SU GWAS at loci including genes involved in urate transport: <italic toggle="yes">SLC2A9, SLC2A11, PDZK1, SLC17A1</italic>. This was done to minimize pleiotropy owing to the established function of the four proteins in directly influencing urate levels and without robust evidence for a role in other physiological processes. F-statistics were calculated for each SNP from both the gout and SU GWAS, as described previously (<xref rid="R21" ref-type="bibr">21</xref>). A full list of all SNPs used for the non-hyperuricemia compartment of gout, all proxy variants selected, and a list of all SNPs used to represent urate transporter genes are available in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 1</xref>. Proxy variants were selected when a SNP in the IV was not present in the prostate cancer GWAS. Proxies were selected by identifying variants in high LD (r<sup>2</sup> &#x0003e; 0.95) and selecting the top variant available in both the SU/gout and prostate cancer GWAS,</p><p id="P11">We also conducted the reverse MR, i.e. testing prostate cancer for causality of gout and SU. Due to the large number of significant risk variants in the source prostate cancer GWAS (451 risk variants were identified by Wang, et al.) (<xref rid="R20" ref-type="bibr">20</xref>), we selected only the most significant SNPs (<italic toggle="yes">P</italic> &#x0003c; 1e-80) to reduce the risk of pleiotropy. The IV was identified by first identifying loci with SNPs associated with prostate cancer at a level of <italic toggle="yes">P</italic> &#x0003c; 1e-50. After these loci were identified, we selected only the top SNP from each locus, keeping only SNPs with <italic toggle="yes">P</italic> &#x0003c; 1e-80. This resulted in a set of 18 SNPs (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 2</xref>).</p><p id="P12">For these IVs to be valid, they each should fulfill the assumptions necessary for MR: [1] all selected IVs are significantly associated with the exposure (F-Statistic &#x0003e; 10); [2] IVs are independent of confounders that could affect both the exposure and outcome; [3] IVs influence the outcome only through the exposure (<xref rid="R15" ref-type="bibr">15</xref>). We did not evaluate assumption 2 because we did not identify any obvious conditions that may be potential confounders or mediators between gout/SU and prostate cancer. Assumption 3 was tested using MR-Egger, which accounts for potential horizontal pleiotropic effects between the exposure and outcomes (<xref rid="R15" ref-type="bibr">15</xref>).</p><p id="P13">Three main methods of MR were used: inverse-variance-weighted MR (IVW), MR-Egger regression, and weighted median. Additional sensitivity analyses included penalized IVW and the exclusion of outlier SNPs. All MR analyses used R 4.3.1, and the MendelianRandomization package (<xref rid="R22" ref-type="bibr">22</xref>). For all MR analyses, we used the effect size for the outcome as the response variable and the effect size for the exposure as the predictor variable. This resulted in two main relationships being tested: [1] the non-hyperuricemia compartment of gout to be causal of prostate cancer; [2] SU to be causal of prostate cancer. The reverse relationships were also tested: [1] prostate cancer to be causal of gout; and [2] prostate cancer to be causal of SU.</p><p id="P14">After MR analysis, we examined whether the SNPs driving the MR results acted as potential expression quantitative trait loci (eQTL) in the following tissues from the Genotype-Tissue Expression (GTEx) data (<xref rid="R22" ref-type="bibr">22</xref>): whole blood, prostate, cultured fibroblast cells, Epstein-Barr-virus (EBV)-transformed lymphocytes, and testis. The data for these analyses were obtained from dbGaP accession number phs000424.v10.p2, and European GTEx v8 eQTL data were used. Colocalization results were sourced from Major et al (<xref rid="R19" ref-type="bibr">19</xref>).</p></sec></sec><sec id="S9"><title>Results</title><sec id="S10"><title>Gout to prostate cancer Mendelian randomization</title><p id="P15">Using the weighted median method we observed evidence that gout may be causal of prostate cancer (OR: 1.18; 95% CI: 1.03&#x02013;1.35; P=0.01; <xref rid="T1" ref-type="table">Table 1</xref>; <xref rid="F1" ref-type="fig">Figure 1</xref>) although this was not supported using the IVW method (IVW: OR: 1.10; 95% CI: 0.92&#x02013;1.31; P=0.29; <xref rid="T1" ref-type="table">Table 1</xref>; <xref rid="F1" ref-type="fig">Figure 1</xref>). MR-Egger showed no evidence of horizontal pleiotropy (Intercept: &#x02212;0.010; SE: 0.010; P=0.33; <xref rid="T1" ref-type="table">Table 1</xref>). Sensitivity analysis using the penalized IVW method to handle potential outliers supported our hypothesis that gout is causal of prostate cancer (OR: 1.16; 95% CI: 1.03&#x02013;1.31; P=0.01; <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 3</xref>). The result of all gout non-hyperuricemia compartment SNPs is available in <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 1</xref>. The gout risk alleles of three SNPs, rs2560449, rs17767183, and rs9973741, drove this causal relationship, while the gout risk allele of one SNP, rs2395180, was significantly protective of prostate cancer.</p><p id="P16">LocusZoom plots were generated for each SNP that significantly contributed to the positive association between gout and prostate cancer, and each SNP was assigned to the closest gene: <italic toggle="yes">SLC30A5</italic> (rs2560449; <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 2</xref>), <italic toggle="yes">IL1R1</italic> (rs17767183; <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 3</xref>), <italic toggle="yes">IL1RN</italic> (rs9973741; <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 4</xref>). Even though rs9973741 is in very close proximity to both <italic toggle="yes">IL1RN</italic> and <italic toggle="yes">IL1F10</italic>, we only assigned it to <italic toggle="yes">IL1RN</italic> since I<italic toggle="yes">L1F10</italic> is only expressed in skin tissue (GTEx). We noted that rs2395180 was located in the <italic toggle="yes">HLA</italic> locus, in close proximity to a number of genes (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 5</xref>). Using the Major et al. data (<xref rid="R19" ref-type="bibr">19</xref>) we identified one potentially colocalizing eQTL from the SNPs and tissues of interest: rs9973741 with <italic toggle="yes">IL1RN</italic> expression in the testis (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 4</xref>; <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 6</xref>). The <italic toggle="yes">IL1RN</italic> eQTL signal overlaps only with gout, and not with prostate cancer (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 6</xref>).</p><p id="P17">We conducted a secondary analysis excluding rs2395180 as a clear outlier with non-overlapping 95% confidence intervals (CI) with other variants in the IV and being in a locus with erratic association with gout, perhaps driven by (uncorrected) population structure (<xref rid="R23" ref-type="bibr">23</xref>). In this analysis, IVW, weighted median, and penalized IVW methods all showed causal effects of gout on prostate cancer (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 3</xref>).</p></sec><sec id="S11"><title>Serum urate to prostate cancer Mendelian randomization</title><p id="P18">Using the IVW method, there was no evidence that genetically predicted SU was causal of prostate cancer (OR: 1.00; 95% CI: 0.97&#x02013;1.02; <italic toggle="yes">P</italic> = 0.83; <xref rid="T1" ref-type="table">Table 1</xref>; <xref rid="F3" ref-type="fig">Figure 3</xref>). This lack of causal relationship was also seen in the weighted median analysis (OR: 1.00; 95% CI: 0.98&#x02013;1.02; P=0.97; <xref rid="T1" ref-type="table">Table 1</xref>; <xref rid="F3" ref-type="fig">Figure 3</xref>). Additionally, MR-Egger showed no evidence for horizontal pleiotropy (Intercept: 0.004; SE: 0.017; P=0.80; <xref rid="T1" ref-type="table">Table 1</xref>). No individual SNPs were significantly associated.</p></sec><sec id="S12"><title>Prostate cancer to serum urate and gout Mendelian randomization</title><p id="P19">There was no evidence that genetically predicted prostate cancer was causal of gout using either the IVW (OR: 0.99; 95% CI: 0.96&#x02013;1.02; <italic toggle="yes">P</italic> = 0.61; <xref rid="T1" ref-type="table">Table 1</xref>) or weighted median MR methods (OR: 0.99; 95% CI: 0.96&#x02013;1.02; <italic toggle="yes">P</italic> = 0.53; <xref rid="T1" ref-type="table">Table 1</xref>). There was also no evidence that genetically predicted prostate cancer was causal of SU using either the IVW method (OR: 1.01; 95% CI: 0.93&#x02013;1.09; <italic toggle="yes">P</italic> = 0.89; <xref rid="T1" ref-type="table">Table 1</xref>) or the weighted median method (OR: 1.02; 95% CI: 0.95&#x02013;1.10; <italic toggle="yes">P</italic> = 0.53; <xref rid="T1" ref-type="table">Table 1</xref>). Additionally, MR-Egger showed no evidence for horizontal pleiotropy in either gout (Intercept: 0.005; SE: 0.007; P=0.47; <xref rid="T1" ref-type="table">Table 1</xref>) or SU (Intercept: 0.001; SE: 0.020; P=0.97; <xref rid="T1" ref-type="table">Table 1</xref>).</p></sec></sec><sec id="S13"><title>Discussion</title><p id="P20">Our study tested whether the non-hyperuricemia compartment of gout and SU are causal of prostate cancer in men of European ancestry. We assessed this using a two-sample MR analysis in men and found evidence supporting a causal relationship between gout inflammation (two of the three positively association variants were in loci encoding genes central to IL-1&#x003b2; signaling) and prostate cancer. There was no evidence for a causal relationship for SU on prostate cancer, or for prostate cancer on gout or SU.</p><p id="P21">Our findings align with previous MR findings that SU is not causal of prostate cancer among European males (<xref rid="R18" ref-type="bibr">18</xref>), although there have been mixed findings from MR studies in East Asians and in observational studies, with observational studies showing differences in SU levels in those with prostate cancer vs those without (<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R24" ref-type="bibr">24</xref>&#x02013;<xref rid="R26" ref-type="bibr">26</xref>). However, none of these studies assessed the reverse relationships or gout-causing inflammatory factors, and observational studies cannot infer causality.</p><p id="P22">To our knowledge this is the first evidence that the non-hyperuricemia compartment of gout may be causal of prostate cancer. There have been observational studies of gout and prostate cancer, but the results have been conflicting. In one cohort study of Taiwanese patients with 8,408 male gout patients and 25,010 age-matched and time-of-diagnosis-matched controls, gout patients were 3 times more likely to develop prostate cancer when compared to the non-gout population (<xref rid="R27" ref-type="bibr">27</xref>). In another Taiwanese cohort study including 355,278 male patients, 25,943 of whom had gout, gout patients were 1.7 times more likely to develop prostate cancer than non-gout patients (<xref rid="R28" ref-type="bibr">28</xref>). However, in a Korean health insurance data study of 179,930 age-matched gout patients and non-gout controls, men with prostate cancer had a lower incidence rate of gout when compared to age-matched non-gout controls (<xref rid="R29" ref-type="bibr">29</xref>). In another study of hospital discharges in Sweden, there was no association between gout and the incidence of prostate cancer (<xref rid="R30" ref-type="bibr">30</xref>).</p><p id="P23">Our MR study identified three genes driving the relationship between the non-hyperuricemia compartment of gout and prostate cancer: <italic toggle="yes">IL1R1</italic> (rs17767183), <italic toggle="yes">IL1RN</italic> (rs9973741), and <italic toggle="yes">SLC30A5</italic> (rs2560449). <italic toggle="yes">IL1R1</italic> (<xref rid="R31" ref-type="bibr">31</xref>), <italic toggle="yes">Il1RN</italic> (<xref rid="R32" ref-type="bibr">32</xref>), and <italic toggle="yes">SLC30A5</italic> (<xref rid="R33" ref-type="bibr">33</xref>) have all been previously implicated in prostate cancer. The IL1 pathway has been shown to play a role in both the development and progression of prostate cancer, though the exact mechanism is still unknown (<xref rid="R31" ref-type="bibr">31</xref>, <xref rid="R32" ref-type="bibr">32</xref>). Additionally, depleted zinc concentration is associated with prostate cancer progression, and zinc transporter <italic toggle="yes">SLC30A5</italic> has been shown to be downregulated in cancerous tissue (<xref rid="R33" ref-type="bibr">33</xref>). Though we do not fully understand the mechanisms via which these SNPs may be causal of prostate cancer, it is notable that two of the top SNPs are both involved in the same inflammatory pathway (the IL1 pathway) with the protein encoded by <italic toggle="yes">IL1RN</italic> (IL1-RA) being an antagonist for IL1-R1 which is also a receptor for the key gout cytokine IL-1&#x003b2;. This biological linkage supports the hypothesis that prostatic inflammation, perhaps triggered by MSU crystals, is a risk factor for prostate cancer.</p><p id="P24">We hypothesize that the deposition and accumulation of MSU crystals in the prostate (<xref rid="R10" ref-type="bibr">10</xref>) may induce a proinflammatory state in prostatic tissue with shared pathways to those in gout inflammation. Men with gout would have increased proclivity to respond to MSU crystals deposited in the prostate. <italic toggle="yes">IL1R1</italic> encodes an <italic toggle="yes">IL-1</italic> receptor protein which binds IL-1&#x003b1; and IL-1&#x003b2;, and <italic toggle="yes">IL1RN</italic> encodes for an IL1 receptor antagonist (IL1-RA), which mediates IL-1&#x003b1; and IL-1&#x003b2; activity and inflammation. In eQTL analysis, rs9973741 (allele G, which is the risk allele for gout) associated with decreased expression of IL1RN in the prostate and decreased expression of both <italic toggle="yes">IL1RN</italic> and <italic toggle="yes">IL1R1</italic> in whole blood, while increasing <italic toggle="yes">IL1RN</italic> expression in the testes. This indicates that the putative pathway may involve complex patterns of regulation of gene expression. Further validation of our findings may lead to significant clinical treatments to mitigate the risk of prostate cancer, such as the use of urate lowering therapies to reduce prostatic inflammation. Notably allopurinol has previously been used to reduce symptoms of non-bacterial prostatitis (<xref rid="R34" ref-type="bibr">34</xref>, <xref rid="R35" ref-type="bibr">35</xref>).</p><p id="P25">The exact mechanisms by which <italic toggle="yes">SLC30A5</italic> may contribute to a causal relationship is less clear. <italic toggle="yes">SLC30A5</italic> encodes for ZnT5 and transports zinc into membrane-bound organelles and out of the cell and is vital in maintaining zinc homeostasis (<xref rid="R36" ref-type="bibr">36</xref>). ZnT5 has been shown to be downregulated in prostate cancer tissue, and this downregulation is an early event in prostate cancer progression (<xref rid="R33" ref-type="bibr">33</xref>, <xref rid="R37" ref-type="bibr">37</xref>).</p><p id="P26">Our study has various strengths. We utilized a two-sample MR analysis, which allowed for finding causal genetic relationships. We used SNPs representing specific aspects of gout risk and SU level, rather than using all SNPs which were significantly associated with gout, which allowed us to test specific mechanistic hypotheses. We included only men in the various genetic datasets used in our study. We tested the causal associations using three methods, IVW, weighted median, and MR-Egger, which robustly test for causal relationships and test for horizontal pleiotropy. However, our study also has limitations. We only included European men in our analysis, which means that these results may not be applicable to other populations. Even though we conducted tests for horizontal pleiotropy, the MR-Egger test does not guarantee that no pleiotropy exists, and we did not conduct extensive checks for vertical pleiotropy. Owing to lack of independent datasets, we were unable to include replication in the study design. Additionally, our study used genetic predictors of SU levels rather than of prostatic urate levels. The collective evidence supports that the prostate produces urate, but genetic predictors of serum urate levels may not reflect those of prostate urate level.</p><p id="P27">In conclusion, our MR analyses of a European male population provided evidence for a causal relationship between the non-hyperuricemia compartment of gout and prostate cancer, but not between SU and prostate cancer. These results suggest that clinical intervention to reduce gout-caused inflammation may reduce prostate cancer risk.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data"><label>Supplement 1</label><media xlink:href="media-1.pdf" id="d67e594" position="anchor"/></supplementary-material></sec></body><back><ack id="S14"><title>Grant Support/Acknowledgments:</title><p id="P28">JAS is supported by research grants from the Patient-Centered Outcomes Research Institute (PCORI; CER-2020C1-19193; SDM-2017C2&#x02013;8224) and the National Institutes of Arthritis, Musculoskeletal and Skin Diseases (NIAMS; P50 AR060772). JAS is also supported by the resources and the use of facilities at the VA Medical Center at Houston, Texas, and by the Center for Innovations in Quality, Effectiveness and Safety (#CIN 13&#x02013;413), Houston, Texas.</p></ack><fn-group><fn fn-type="COI-statement" id="FN2"><p id="P29">Conflict of Interest:</p><p id="P30">All authors except JAS declare that they have no conflicts of interest relevant to this study. JAS has received consultant fees from ROMTech, Atheneum, Clearview healthcare partners, American College of Rheumatology, Yale, Hulio, Horizon Pharmaceuticals/DINORA, ANI/Exeltis, USA Inc., Frictionless Solutions, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, and Practice Point communications; the National Institutes of Health; and the American College of Rheumatology. JAS has received institutional research support from Zimmer Biomet Holdings. JAS received food and beverage payments from Intuitive Surgical Inc./Philips Electronics North America. JAS owns stock options in Atai life sciences, Kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix Pharmaceuticals Holding Corp., Aebona Pharmaceuticals, and Charlotte&#x02019;s Web Holdings, Inc. JAS previously owned stock options in Amarin, Viking and Moderna pharmaceuticals. JAS is on the speaker&#x02019;s bureau of Simply Speaking.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name><surname>Dalbeth</surname><given-names>N</given-names></name>, <name><surname>Gosling</surname><given-names>AL</given-names></name>, <name><surname>Gaffo</surname><given-names>A</given-names></name>, <name><surname>Abhishek</surname><given-names>A</given-names></name>. <source>Gout. Lancet</source>. <year>2021</year>;<volume>397</volume>(<issue>10287</issue>):<fpage>1843</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">33798500</pub-id>
</mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Colantonio</surname><given-names>LD</given-names></name>, <name><surname>Saag</surname><given-names>KG</given-names></name>, <name><surname>Singh</surname><given-names>JA</given-names></name>, <name><surname>Chen</surname><given-names>L</given-names></name>, <name><surname>Reynolds</surname><given-names>RJ</given-names></name>, <name><surname>Gaffo</surname><given-names>A</given-names></name>, <etal/>
<article-title>Gout is associated with an increased risk for incident heart failure among older adults: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study</article-title>. <source>Arthritis Res Ther</source>. <year>2020</year>;<volume>22</volume>(<issue>1</issue>):<fpage>86</fpage>.<pub-id pub-id-type="pmid">32299504</pub-id>
</mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>Y</given-names></name>, <name><surname>Pandya</surname><given-names>BJ</given-names></name>, <name><surname>Choi</surname><given-names>HK</given-names></name>. <article-title>Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007&#x02013;2008</article-title>. <source>Am J Med</source>. <year>2012</year>;<volume>125</volume>(<issue>7</issue>):<fpage>679</fpage>&#x02013;<lpage>87 e1</lpage>.<pub-id pub-id-type="pmid">22626509</pub-id>
</mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Yokose</surname><given-names>C</given-names></name>, <name><surname>McCormick</surname><given-names>N</given-names></name>, <name><surname>Lu</surname><given-names>N</given-names></name>, <name><surname>Tanikella</surname><given-names>S</given-names></name>, <name><surname>Lin</surname><given-names>K</given-names></name>, <name><surname>Joshi</surname><given-names>AD</given-names></name>, <etal/>
<article-title>Trends in Prevalence of Gout Among US Asian Adults, 2011&#x02013;2018</article-title>. <source>JAMA Netw Open</source>. <year>2023</year>;<volume>6</volume>(<issue>4</issue>):<fpage>e239501</fpage>.<pub-id pub-id-type="pmid">37083663</pub-id>
</mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Chen-Xu</surname><given-names>M</given-names></name>, <name><surname>Yokose</surname><given-names>C</given-names></name>, <name><surname>Rai</surname><given-names>SK</given-names></name>, <name><surname>Pillinger</surname><given-names>MH</given-names></name>, <name><surname>Choi</surname><given-names>HK</given-names></name>. <article-title>Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007&#x02013;2016</article-title>. <source>Arthritis Rheumatol</source>. <year>2019</year>;<volume>71</volume>(<issue>6</issue>):<fpage>991</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30618180</pub-id>
</mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Halperin Kuhns</surname><given-names>VL</given-names></name>, <name><surname>Woodward</surname><given-names>OM</given-names></name>. <article-title>Sex Differences in Urate Handling</article-title>. <source>Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>(<issue>12</issue>).</mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Liu-Bryan</surname><given-names>R</given-names></name>, <name><surname>Guo</surname><given-names>T</given-names></name>, <name><surname>Lee</surname><given-names>J</given-names></name>, <name><surname>Terkeltaub</surname><given-names>R</given-names></name>. <article-title>Atherogenic Activation of Human Vascular Smooth Muscle Cells by Monosodium Urate Crystals</article-title>. <source>Gout, Urate, and Crystal Deposition Disease</source>. <year>2023</year>;<volume>1</volume>(<issue>3</issue>):<fpage>192</fpage>&#x02013;<lpage>207</lpage>.</mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Srivastava</surname><given-names>A</given-names></name>, <name><surname>Chopra</surname><given-names>SK</given-names></name>, <name><surname>Dasgupta</surname><given-names>PR</given-names></name>. <article-title>Biochemical analysis of human seminal plasma. II. Protein, non-protein nitrogen, urea, uric acid and creatine</article-title>. <source>Andrologia</source>. <year>1984</year>;<volume>16</volume>(<issue>3</issue>):<fpage>265</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">6465552</pub-id>
</mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>HY</given-names></name>, <name><surname>Lu</surname><given-names>JC</given-names></name>, <name><surname>Zhang</surname><given-names>RS</given-names></name>, <name><surname>Xia</surname><given-names>YX</given-names></name>, <name><surname>Huang</surname><given-names>YF</given-names></name>. [<article-title>Determination of uric acid in seminal plasma and correlation between seminal uric acid and semen parameters</article-title>]. <source>Zhonghua Nan Ke Xue</source>. <year>2007</year>;<volume>13</volume>(<issue>11</issue>):<fpage>1016</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">18077916</pub-id>
</mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>JJ</given-names></name>, <name><surname>Roudier</surname><given-names>MP</given-names></name>, <name><surname>Soman</surname><given-names>D</given-names></name>, <name><surname>Mokadam</surname><given-names>NA</given-names></name>, <name><surname>Simkin</surname><given-names>PA</given-names></name>. <article-title>Prevalence of birefringent crystals in cardiac and prostatic tissues, an observational study</article-title>. <source>BMJ Open</source>. <year>2014</year>;<volume>4</volume>(<issue>7</issue>):<fpage>e005308</fpage>.</mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>WM</given-names></name>, <name><surname>Pasaribu</surname><given-names>N</given-names></name>, <name><surname>Lee</surname><given-names>SS</given-names></name>, <name><surname>Tsai</surname><given-names>WC</given-names></name>, <name><surname>Li</surname><given-names>CY</given-names></name>, <name><surname>Lin</surname><given-names>GT</given-names></name>, <etal/>
<article-title>Risk of incident benign prostatic hyperplasia in patients with gout: a retrospective cohort study</article-title>. <source>Prostate Cancer Prostatic Dis</source>. <year>2018</year>;<volume>21</volume>(<issue>2</issue>):<fpage>277</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">29858589</pub-id>
</mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Kukko</surname><given-names>V</given-names></name>, <name><surname>Kaipia</surname><given-names>A</given-names></name>, <name><surname>Talala</surname><given-names>K</given-names></name>, <name><surname>Taari</surname><given-names>K</given-names></name>, <name><surname>Tammela</surname><given-names>TLJ</given-names></name>, <name><surname>Auvinen</surname><given-names>A</given-names></name>, <etal/>
<article-title>Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort</article-title>. <source>Prostate Cancer Prostatic Dis</source>. <year>2018</year>;<volume>21</volume>(<issue>3</issue>):<fpage>373</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">29273728</pub-id>
</mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Ou</surname><given-names>G</given-names></name>, <name><surname>Li</surname><given-names>R</given-names></name>, <name><surname>Peng</surname><given-names>L</given-names></name>, <name><surname>Shi</surname><given-names>J</given-names></name>. <article-title>Causal relationship between benign prostatic hyperplasia and prostate cancer: a bidirectional Mendelian randomization analysis</article-title>. <source>Postgrad Med J</source>. <year>2024</year>.</mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Orsted</surname><given-names>DD</given-names></name>, <name><surname>Bojesen</surname><given-names>SE</given-names></name>. <article-title>The link between benign prostatic hyperplasia and prostate cancer</article-title>. <source>Nat Rev Urol</source>. <year>2013</year>;<volume>10</volume>(<issue>1</issue>):<fpage>49</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">23165396</pub-id>
</mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>de Leeuw</surname><given-names>C</given-names></name>, <name><surname>Savage</surname><given-names>J</given-names></name>, <name><surname>Bucur</surname><given-names>IG</given-names></name>, <name><surname>Heskes</surname><given-names>T</given-names></name>, <name><surname>Posthuma</surname><given-names>D</given-names></name>. <article-title>Understanding the assumptions underlying Mendelian randomization</article-title>. <source>Eur J Hum Genet</source>. <year>2022</year>;<volume>30</volume>(<issue>6</issue>):<fpage>653</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">35082398</pub-id>
</mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Davies</surname><given-names>NM</given-names></name>, <name><surname>Holmes</surname><given-names>MV</given-names></name>, <name><surname>Davey Smith</surname><given-names>G</given-names></name>. <article-title>Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians</article-title>. <source>BMJ</source>. <year>2018</year>;<volume>362</volume>:<fpage>k601</fpage>.<pub-id pub-id-type="pmid">30002074</pub-id>
</mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name><surname>Deng</surname><given-names>Y</given-names></name>, <name><surname>Huang</surname><given-names>J</given-names></name>, <name><surname>Wong</surname><given-names>MCS</given-names></name>. <article-title>Association between serum uric acid and prostate cancer risk in East Asian populations: a Mendelian randomization study</article-title>. <source>Eur J Nutr</source>. <year>2023</year>;<volume>62</volume>(<issue>3</issue>):<fpage>1323</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">36542132</pub-id>
</mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Jiang</surname><given-names>M</given-names></name>, <name><surname>Ren</surname><given-names>L</given-names></name>, <name><surname>Chen</surname><given-names>S</given-names></name>, <name><surname>Li</surname><given-names>G</given-names></name>. <article-title>Serum Uric Acid Levels and Risk of Eight Site-Specific Cancers: A Mendelian Randomization Study</article-title>. <source>Front Genet</source>. <year>2021</year>;<volume>12</volume>:<fpage>608311</fpage>.<pub-id pub-id-type="pmid">33767728</pub-id>
</mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name><surname>Major</surname><given-names>TJ</given-names></name>, <name><surname>Takei</surname><given-names>R</given-names></name>, <name><surname>Matsuo</surname><given-names>H</given-names></name>, <name><surname>Leask</surname><given-names>MP</given-names></name>, <name><surname>Sumpter</surname><given-names>NA</given-names></name>, <name><surname>Topless</surname><given-names>RK</given-names></name>, <etal/>
<article-title>A genome-wide association analysis reveals new pathogenic pathways in gout</article-title>. <source>Nat Genet</source>. <year>2024</year>;<volume>56</volume>(<issue>11</issue>):<fpage>2392</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">39406924</pub-id>
</mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>A</given-names></name>, <name><surname>Shen</surname><given-names>J</given-names></name>, <name><surname>Rodriguez</surname><given-names>AA</given-names></name>, <name><surname>Saunders</surname><given-names>EJ</given-names></name>, <name><surname>Chen</surname><given-names>F</given-names></name>, <name><surname>Janivara</surname><given-names>R</given-names></name>, <etal/>
<article-title>Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants</article-title>. <source>Nat Genet</source>. <year>2023</year>;<volume>55</volume>(<issue>12</issue>):<fpage>2065</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">37945903</pub-id>
</mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name><surname>Bowden</surname><given-names>J</given-names></name>, <name><surname>Del Greco</surname><given-names>MF</given-names></name>, <name><surname>Minelli</surname><given-names>C</given-names></name>, <name><surname>Zhao</surname><given-names>Q</given-names></name>, <name><surname>Lawlor</surname><given-names>DA</given-names></name>, <name><surname>Sheehan</surname><given-names>NA</given-names></name>, <etal/>
<article-title>Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption</article-title>. <source>Int J Epidemiol</source>. <year>2019</year>;<volume>48</volume>(<issue>3</issue>):<fpage>728</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">30561657</pub-id>
</mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>Burgess</surname><given-names>S</given-names></name>, <name><surname>Yavorska</surname><given-names>O</given-names></name>. <article-title>MendelianRandomization: Mendelian Randomization Package</article-title>. <source>R package version 0.10.0</source>. <year>2024</year>.</mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name><surname>Lokki</surname><given-names>ML</given-names></name>, <name><surname>Paakkanen</surname><given-names>R</given-names></name>. <article-title>The complexity and diversity of major histocompatibility complex challenge disease association studies</article-title>. <source>HLA</source>. <year>2019</year>;<volume>93</volume>(<issue>1</issue>):<fpage>3</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">30468004</pub-id>
</mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>A</given-names></name>, <name><surname>Barber</surname><given-names>JR</given-names></name>, <name><surname>Tin</surname><given-names>A</given-names></name>, <name><surname>De Marzo</surname><given-names>AM</given-names></name>, <name><surname>Kottgen</surname><given-names>A</given-names></name>, <name><surname>Joshu</surname><given-names>CE</given-names></name>, <etal/>
<article-title>Serum Urate, Genetic Variation, and Prostate Cancer Risk: Atherosclerosis Risk in Communities (ARIC) Study</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. <year>2019</year>;<volume>28</volume>(<issue>7</issue>):<fpage>1259</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">31263056</pub-id>
</mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name><surname>Singh</surname><given-names>S</given-names></name>, <name><surname>Jaiswal</surname><given-names>S</given-names></name>, <name><surname>Faujdar</surname><given-names>G</given-names></name>, <name><surname>Priyadarshi</surname><given-names>S</given-names></name>. <article-title>Comparison of serum uric acid levels between localised prostate cancer patients and a control group</article-title>. <source>Urologia</source>. <year>2024</year>;<volume>91</volume>(<issue>2</issue>):<fpage>320</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">38344978</pub-id>
</mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>JW</given-names></name>, <name><surname>Lee</surname><given-names>JH</given-names></name>, <name><surname>Cho</surname><given-names>HJ</given-names></name>, <name><surname>Ha</surname><given-names>YJ</given-names></name>, <name><surname>Kang</surname><given-names>EH</given-names></name>, <name><surname>Shin</surname><given-names>K</given-names></name>, <etal/>
<article-title>Influence of androgen deprivation therapy on serum urate levels in patients with prostate cancer: A retrospective observational study</article-title>. <source>PLoS One</source>. <year>2018</year>;<volume>13</volume>(<issue>12</issue>):<fpage>e0209049</fpage>.<pub-id pub-id-type="pmid">30557349</pub-id>
</mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>CJ</given-names></name>, <name><surname>Yen</surname><given-names>JH</given-names></name>, <name><surname>Chang</surname><given-names>SJ</given-names></name>. <article-title>Gout patients have an increased risk of developing most cancers, especially urological cancers</article-title>. <source>Scand J Rheumatol</source>. <year>2014</year>;<volume>43</volume>(<issue>5</issue>):<fpage>385</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">24825466</pub-id>
</mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Kuo</surname><given-names>CF</given-names></name>, <name><surname>Luo</surname><given-names>SF</given-names></name>, <name><surname>See</surname><given-names>LC</given-names></name>, <name><surname>Chou</surname><given-names>IJ</given-names></name>, <name><surname>Fang</surname><given-names>YF</given-names></name>, <name><surname>Yu</surname><given-names>KH</given-names></name>. <article-title>Increased risk of cancer among gout patients: a nationwide population study</article-title>. <source>Joint Bone Spine</source>. <year>2012</year>;<volume>79</volume>(<issue>4</issue>):<fpage>375</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">22088929</pub-id>
</mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Oh</surname><given-names>YJ</given-names></name>, <name><surname>Lee</surname><given-names>YJ</given-names></name>, <name><surname>Lee</surname><given-names>E</given-names></name>, <name><surname>Park</surname><given-names>B</given-names></name>, <name><surname>Kwon</surname><given-names>JW</given-names></name>, <name><surname>Heo</surname><given-names>J</given-names></name>, <etal/>
<article-title>Cancer risk in Korean patients with gout</article-title>. <source>Korean J Intern Med</source>. <year>2022</year>;<volume>37</volume>(<issue>2</issue>):<fpage>460</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">32872748</pub-id>
</mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name><surname>Boffetta</surname><given-names>P</given-names></name>, <name><surname>Nordenvall</surname><given-names>C</given-names></name>, <name><surname>Nyren</surname><given-names>O</given-names></name>, <name><surname>Ye</surname><given-names>W</given-names></name>. <article-title>A prospective study of gout and cancer</article-title>. <source>Eur J Cancer Prev</source>. <year>2009</year>;<volume>18</volume>(<issue>2</issue>):<fpage>127</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">19337060</pub-id>
</mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><name><surname>Dahl</surname><given-names>HC</given-names></name>, <name><surname>Kanchwala</surname><given-names>M</given-names></name>, <name><surname>Thomas-Jardin</surname><given-names>SE</given-names></name>, <name><surname>Sandhu</surname><given-names>A</given-names></name>, <name><surname>Kanumuri</surname><given-names>P</given-names></name>, <name><surname>Nawas</surname><given-names>AF</given-names></name>, <etal/>
<article-title>Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence</article-title>. <source>PLoS One</source>. <year>2020</year>;<volume>15</volume>(<issue>12</issue>):<fpage>e0242970</fpage>.<pub-id pub-id-type="pmid">33326447</pub-id>
</mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><name><surname>Fan</surname><given-names>YC</given-names></name>, <name><surname>Lee</surname><given-names>KD</given-names></name>, <name><surname>Tsai</surname><given-names>YC</given-names></name>. <article-title>Roles of Interleukin-1 Receptor Antagonist in Prostate Cancer Progression</article-title>. <source>Biomedicines</source>. <year>2020</year>;<volume>8</volume>(<issue>12</issue>).</mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><name><surname>Singh</surname><given-names>CK</given-names></name>, <name><surname>Malas</surname><given-names>KM</given-names></name>, <name><surname>Tydrick</surname><given-names>C</given-names></name>, <name><surname>Siddiqui</surname><given-names>IA</given-names></name>, <name><surname>Iczkowski</surname><given-names>KA</given-names></name>, <name><surname>Ahmad</surname><given-names>N</given-names></name>. <article-title>Analysis of Zinc-Exporters Expression in Prostate Cancer</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>36772</fpage>.<pub-id pub-id-type="pmid">27833104</pub-id>
</mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><name><surname>McNaughton</surname><given-names>CO</given-names></name>, <name><surname>Wilt</surname><given-names>T</given-names></name>. <article-title>Allopurinol for chronic prostatitis</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2002</year>(<issue>4</issue>):<fpage>CD001041</fpage>.<pub-id pub-id-type="pmid">12519549</pub-id>
</mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><name><surname>Persson</surname><given-names>BE</given-names></name>, <name><surname>Ronquist</surname><given-names>G</given-names></name>, <name><surname>Ekblom</surname><given-names>M</given-names></name>. <article-title>Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double-blind controlled study</article-title>. <source>J Urol</source>. <year>1996</year>;<volume>155</volume>(<issue>3</issue>):<fpage>961</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">8583618</pub-id>
</mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><name><surname>Kambe</surname><given-names>T</given-names></name>, <name><surname>Matsunaga</surname><given-names>M</given-names></name>, <name><surname>Takeda</surname><given-names>TA</given-names></name>. <article-title>Understanding the Contribution of Zinc Transporters in the Function of the Early Secretory Pathway</article-title>. <source>Int J Mol Sci</source>. <year>2017</year>;<volume>18</volume>(<issue>10</issue>).</mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><name><surname>Bafaro</surname><given-names>E</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Xu</surname><given-names>Y</given-names></name>, <name><surname>Dempski</surname><given-names>RE</given-names></name>. <article-title>The emerging role of zinc transporters in cellular homeostasis and cancer</article-title>. <source>Signal Transduct Target Ther</source>. <year>2017</year>;<volume>2</volume>:<fpage>17029</fpage>-.<pub-id pub-id-type="pmid">29218234</pub-id>
</mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Figure 1:</label><caption><p id="P31">Forest plot of all Mendelian Randomization tests for the non-hyperuricemia compartment of gout to prostate cancer</p></caption><graphic xlink:href="nihpp-2025.05.09.25327351v1-f0001" position="float"/></fig><fig position="float" id="F2"><label>Figure 2:</label><caption><p id="P32">Forest plot of all Mendelian Randomization tests for the non-hyperuricemia compartment of gout to prostate cancer, excluding outlier (rs2395180)</p></caption><graphic xlink:href="nihpp-2025.05.09.25327351v1-f0002" position="float"/></fig><fig position="float" id="F3"><label>Figure 3:</label><caption><p id="P33">Forest plot of all Mendelian Randomization tests for the urate transporter SNPs to prostate cancer</p></caption><graphic xlink:href="nihpp-2025.05.09.25327351v1-f0003" position="float"/></fig><table-wrap position="float" id="T1"><label>Table 1:</label><caption><p id="P34">Mendelian Randomization Results</p></caption><table frame="hsides" rules="none"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">OR (95% CI)<sup><xref rid="TFN1" ref-type="table-fn">1</xref></sup></th><th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th align="center" valign="bottom" rowspan="1" colspan="1">MR Egger intercept (SE)</th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value of pleiotropy</th></tr><tr><th colspan="5" align="left" valign="middle" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td colspan="5" align="center" valign="top" rowspan="1">
<bold>Gout (Non-hyperuricemia Compartment) to Prostate Cancer &#x02013; Gout GWAS</bold>
</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IVW</td><td align="right" valign="top" rowspan="1" colspan="1">1.10 (0.92&#x02013;1.31)</td><td align="right" valign="top" rowspan="1" colspan="1">0.29</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MR Egger</td><td align="right" valign="top" rowspan="1" colspan="1">1.44 (0.82&#x02013;2.53)</td><td align="right" valign="top" rowspan="1" colspan="1">0.21</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.010 (0.010)</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weighted median</td><td align="right" valign="top" rowspan="1" colspan="1">
<bold>1.18 (1.03&#x02013;1.35)</bold>
</td><td align="right" valign="top" rowspan="1" colspan="1">
<bold>0.01</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td colspan="5" align="center" valign="top" rowspan="1">
<bold>Gout (Non-hyperuricemia Compartment) to Prostate Cancer outliers excluded &#x02013; Gout GWAS</bold>
</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IVW</td><td align="right" valign="top" rowspan="1" colspan="1">
<bold>1.15 (1.01&#x02013;1.30)</bold>
</td><td align="right" valign="top" rowspan="1" colspan="1">
<bold>0.03</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MR Egger</td><td align="right" valign="top" rowspan="1" colspan="1">1.11 (0.72&#x02013;1.71)</td><td align="right" valign="top" rowspan="1" colspan="1">0.64</td><td align="center" valign="top" rowspan="1" colspan="1">0.001 (0.008)</td><td align="center" valign="top" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weighted median</td><td align="right" valign="top" rowspan="1" colspan="1">
<bold>1.18 (1.04&#x02013;1.35)</bold>
</td><td align="right" valign="top" rowspan="1" colspan="1">
<bold>0.01</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td colspan="5" align="center" valign="top" rowspan="1">
<bold>Urate Transporter Genes to Prostate Cancer &#x02013; Urate GWAS</bold>
</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IVW</td><td align="right" valign="top" rowspan="1" colspan="1">1.00 (0.97&#x02013;1.02)</td><td align="right" valign="top" rowspan="1" colspan="1">0.83</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MR Egger</td><td align="right" valign="top" rowspan="1" colspan="1">0.99 (0.89&#x02013;1.09)</td><td align="right" valign="top" rowspan="1" colspan="1">0.77</td><td align="center" valign="top" rowspan="1" colspan="1">0.004 (0.017)</td><td align="center" valign="top" rowspan="1" colspan="1">0.80</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weighted median</td><td align="right" valign="top" rowspan="1" colspan="1">1.00 (0.98&#x02013;1.02)</td><td align="right" valign="top" rowspan="1" colspan="1">0.97</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td colspan="5" align="center" valign="top" rowspan="1">
<bold>Prostate Cancer to Gout &#x02013; Prostate Cancer GWAS</bold>
</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IVW</td><td align="right" valign="top" rowspan="1" colspan="1">0.99 (0.96&#x02013;1.02)</td><td align="right" valign="top" rowspan="1" colspan="1">0.61</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MR Egger</td><td align="right" valign="top" rowspan="1" colspan="1">0.96 (0.89&#x02013;1.05)</td><td align="right" valign="top" rowspan="1" colspan="1">0.39</td><td align="center" valign="top" rowspan="1" colspan="1">0.005 (0.007)</td><td align="center" valign="top" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weighted median</td><td align="right" valign="top" rowspan="1" colspan="1">0.99 (0.96&#x02013;1.02)</td><td align="right" valign="top" rowspan="1" colspan="1">0.55</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td colspan="5" align="center" valign="top" rowspan="1">
<bold>Prostate Cancer to Serum Urate &#x02013; Prostate Cancer GWAS</bold>
</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">
<hr/>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IVW</td><td align="right" valign="top" rowspan="1" colspan="1">1.01 (0.93&#x02013;1.09)</td><td align="right" valign="top" rowspan="1" colspan="1">0.89</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MR Egger</td><td align="right" valign="top" rowspan="1" colspan="1">1.00 (0.80&#x02013;1.25)</td><td align="right" valign="top" rowspan="1" colspan="1">0.99</td><td align="center" valign="top" rowspan="1" colspan="1">0.001 (0.020)</td><td align="center" valign="top" rowspan="1" colspan="1">0.97</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weighted median</td><td align="right" valign="top" rowspan="1" colspan="1">1.02 (0.95&#x02013;1.10)</td><td align="right" valign="top" rowspan="1" colspan="1">0.53</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>1</label><p id="P35">Odds ratios represent the change in risk of prostate cancer as the genetic risk of gout increases (Gout GWAS) and the change in risk of prostate cancer per mg/dL change in serum urate (Urate GWAS)</p></fn></table-wrap-foot></table-wrap></floats-group></article>